New biomarkers of Crohn's disease: Serum biomarkers and development of diagnostic tools

Expert Review of Molecular Diagnostics

Volumn 8, Issue 3, 2008, Pages 327-337

  Meuwis, Marie Alice ^b   Fillet, Marianne ^b   Chapelle, Jean Paul ^c   Malaise, Michel ^b   Louis, Edouard ^b   Merville, Marie Paule ^a,b  

^a GIGA Research Institute   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antibody; Biomarker; C reactive protein; Crohn's disease; Inflammatory bowel disease; Microarray; Proteomics; Ulcerative colitis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INFLIXIMAB; PROTEOME;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; BIOINFORMATICS; CLINICAL ASSESSMENT TOOL; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; IMMUNE RESPONSE; MATHEMATICAL ANALYSIS; MICROARRAY ANALYSIS; NANOTECHNOLOGY; NONHUMAN; PHAGE DISPLAY; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ACUTE-PHASE PROTEINS; AUTOANTIBODIES; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS;

EID: 44249103536     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.3.327     Document Type: Review

References (100)

1. Crohn BB, L Ginzburg, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. JAMA 251(1), 73-79 (1984)
2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573), 1641-1657 (2007).
3. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19(Suppl. A), 5-36 (2005).
4. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm. Bowel Dis. 6(1), 8-15 (2000).
5. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J. Gastroenterol. 12(1), 75-81 (2006).
6. Travis SP, Stange EF, Lémann M et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55(Suppl. 1), I16-I35 (2006).
7. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment. Pharmacol. Ther. 17(Suppl. 2), 11-17 (2003).
8. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 133(5), 1670-1689 (2007).
9. Zilberman L, Maharshak N, Arbel Y et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion 73(4), 205-209 (2006).
10. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm. Bowel Dis. 10(5), 661-665 (2004).
11. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis. 11(8), 707-712 (2005).
12. Louis E, Vermeire S, Rutgeerts P et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37(7), 818-824 (2002).
13. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 12(6), 524-534 (2006).
14. Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 54(3), 321-322 (2005).
15. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut 32(8), 913-917 (1991).
16. Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-α is not elevated in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 12(2), 233-236 (1991).
17. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199(1), 28-35 (2003).
18. Puleston J, Cooper M, Murch S et al. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment. Pharmacol. Ther. 21(2), 109-120 (2005).
19. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am. J. Gastroenterol. 95(2), 359-367 (2000).
20. Mitsuyama K, Tsuruta O, Tomiyasu N et al. Increased circulating concentrations of growth-related oncogene (GRO)-α in patients with inflammatory bowel disease. Dig. Dis. Sci. 51(1), 173-177 (2006).
21. Kader HA, Tchernev VT, Satyaraj E et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am. J. Gastroenterol. 100(2), 414-423 (2005).
22. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 99(5), 938-945 (2004).
23. Ohkawa R, Hirowatari Y, Nakamura K et al. Platelet release of β-thromboglobulin and platelet factor 4 and serotonin in plasma samples. Clin. Biochem. 38(11), 1023-1026 (2005).
24. Andoh A, Yoshida T, Yagi Y et al. Increased aggregation response of platelets in patients with inflammatory bowel disease. J. Gastroenterol. 41(1), 47-54 (2006).
25. Sato T, Nakai T, Tamura N et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 54(9), 1254-1262 (2005).
26. Haapamäki MM, Grönroos J, Nurmi H, Irjala K, Peuravuori H, Nevalainen TJ. Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease. Scand. J. Clin. Lab. Invest. 66(7), 585-593 (2006).
27. Grønbaek H, Vestergaard EM, Hey H, Nielsen JN, Nexø E. Serum trefoil factors in patients with inflammatory bowel disease. Digestion 74(1), 33-39 (2006).
28. Vestergaard EM, Poulsen SS, Grønbaek H et al. Development and evaluation of an ELISA for human trefoil factor 3. Clin. Chem. 48(10), 1689-1695 (2002).
29. Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA. Serum angiogenin in inflammatory bowel disease. Dig. Dis. Sci. 49(11-12), 1758-1762 (2004).
30. Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur. J. Clin. Invest. 36(2), 127-132 (2006).
31. Satsangi J, Sutherland LR. Inflammatory bowel diseases. Churchill Livingstone, Oxford, UK (2003).
32. Broedl UC, Schachinger V, Lingenhel A et al. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13(4), 391-397 (2007).
33. Herrlinger KR, Dittmann R, Weitz G et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm. Bowel Dis. 10(3), 229-233 (2004).
34. Pastor Rojo O, López San Román A, Albéniz Arbizu E, de la Hera Martínez A, Ripoll Sevillano E, Albillos Martínez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13(3), 269-277 (2007).
35. Oshimoto H, Okamura S, Iida T, Ishikawa T, Hosaka K, Mori M. Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease. Tohoku J. Exp. Med. 207(1), 65-71 (2005).
36. Adams RJ, Heazlewood SP, Gilshenan KS, O'Brien M, McGuckin MA, Florin TH. IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am. J. Gastroenterol. (2007).
37. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev. Gastroenterol. Disord. 4(4), 167-174 (2004).
38. Standaert-Vitse A, Jouault T, Vandewalle P et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 130(6), 1764-1775 (2006).
39. Desplat-Jégo S, Johanet C, Escande A et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J. Gastroenterol. 13(16), 2312-2318 (2007).
40. Sutton CL, Kim J, Yamane A et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119(1), 23-31 (2000).
41. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect. Immun. 70(12), 6567-6575 (2002).
42. Lodes MJ, Cong Y, Elson CO et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113(9), 1296-1306 (2004).
43. Dubinsky MC, Lin YC, Dutridge D et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am. J. Gastroenterol. 101(2), 360-367 (2006).
44. Dotan I, Fishman S, Dgani Y et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131(2), 366-378 (2006).
45. Abreu MT. Serologies in Crohn's disease: can we change the gray zone to black and white? Gastroenterology 131(2), 664-667 (2006).
46. Arnott ID, Landers CJ, Nimmo EJ et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99(12), 2376-2384 (2004).
47. Mei L, Targan SR, Landers CJ et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 130(4), 1078-1085 (2006).
48. Cruyssen BV, Peeters H, Hoffman IE et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin. Exp. Immunol. 140(2), 354-9 (2005).
49. Halfvarson J, Standaert-Vitse A, Järnerot G et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 54(9), 1237-1243 (2005).
50. Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig. Dis. Sci. 52(1), 33-39 (2007).
51. Muratori P, Muratori L, Guidi M et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin. Exp. Immunol. 132(3), 473-476 (2003).
52. Fresko I, Ugurlu S, Ozbakir F et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome. Clin. Exp. Rheumatol. 23(4 Suppl. 38), S67-S70 (2005).
53. Condino AA, Hoffenberg EJ, Accurso F et al. Frequency of ASCA seropositivity in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 41(1), 23-26 (2005).
54. Linskens RK, Mallant-Hent RC, Groothuismink ZM et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur. J. Gastroenterol. Hepatol. 14(9), 1013-1018 (2002).
55. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42(6), 788-791 (1998).
56. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am. J. Gastroenterol. 96(3), 730-734 (2001).
57. Joossens S, Daperno M, Shums Z et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin. Chem. 50(8), 1422-1425 (2004).
58. Seibold F, Mörk H, Tanza S et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 40(4), 481-484 (1997).
59. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 32(10), 1192-1197 (1991).
60. Joossens S, Vermeire S, Van Steen K et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm. Bowel Dis. 10(6), 771-777 (2004).
61. Rahbar A, Bostrom L, Soderberg-Naucler C. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease. J. Autoimmun. 26(3), 155-164 (2006).
62. Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 119(1), E193-E199 (2007).
63. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 99(11), 2235-2241 (2004).
64. Israeli E, Grotto I, Gilburd B et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54(9), 1232-1236 (2005).
65. Seibold F. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut 54(9), 1212-1213 (2005).
66. Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126(2), 414-424 (2004).
67. Joossens S, Reinisch W, Vermeire S et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122(5), 1242-1247 (2002).
68. Tremelling M, Cummings F, Fisher SA et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 132(5), 1657-1664 (2007).
69. Raelson JV, Little RD, Ruether A et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc. Natl Acad. Sci. USA 104(37), 14747-14752 (2007).
70. Libioulle C, Louis E, Hansoul S et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 3(4), E58 (2007).
71. Noble C, Nimmo E, Gaya D, Russell RK, Satsangi J. Novel susceptibility genes in inflammatory bowel disease. World J. Gastroenterol. 12(13), 1991-1999 (2006).
72. Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver MJ. Technology insight: tuning into the genetic orchestra using microarrays - limitations of DNA microarrays in clinical practice. Nat. Clin. Pract. Oncol. 3(9), 501-516 (2006).
73. Warner EE, Dieckgraefe BK. Application of genome-wide gene expression profiling by high-density DNA arrays to the treatment and study of inflammatory bowel disease. Inflamm. Bowel Dis. 8(2), 140-157 (2002).
74. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum. Mol. Genet. 10(5), 445-456 (2001).
75. Langmann T, Moehle C, Mauerer R et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127(1), 26-40 (2004).
76. Okahara S, Arimura Y, Yabana T et al. Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis. Aliment. Pharmacol. Ther. 21(9), 1091-1097 (2005).
77. Galamb O, Sipos F, Dinya E, Spisak S, Tulassay Z, Molnar B. mRNA expression, functional profiling and multivariate classification of colon biopsy specimen by cDNA overall glass microarray. World J. Gastroenterol. 12(43), 6998-7006 (2006).
78. Csillag C, Nielsen OH, Borup R, Nielsen FC, Olsen J. Clinical phenotype and gene expression profile in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 292(1), G298-G304 (2007).
79. Csillag C, Nielsen OH, Borup R, Nielsen FC. Microarrays and Crohn's disease: collecting reliable information. Scand. J. Gastroenterol. 40(4), 369-377 (2005).
80. Wu F, Dassopoulos T, Cope L et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm. Bowel Dis. 13(7), 807-821 (2007).
81. Costello CM, Mah N, Häsler R et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2(8), E199 (2005).
82. Bovin LF, Brynskov J, Hegedüs L, Jess T, Nielsen CH, Bendtzen K. Gene expression profiling in autoimmune diseases: chronic inflammation or disease specific patterns? Autoimmunity 40(3), 191-201 (2007).
83. Burczynski ME, Peterson RL, Twine NC et al. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn. 8(1), 51-61 (2006).
84. Din S, Lennon AM, Arnott ID, Hupp T, Satsangi J. Technology insight: the application of proteomics in gastrointestinal disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 4(7), 372-385 (2007).
85. Barceló-Batllori S, André M, Servis C et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2(5), 551-560 (2002).
86. Felley-Bosco E, Andre M. Proteomics and chronic inflammatory bowel diseases. Pathol. Res. Pract. 200(2), 129-133 (2004).
87. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
88. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 53(5), 852-858 (2007).
89. Meuwis MA, Fillet M, Geurts P et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem. Pharmacol. 73(9), 1422-1433 (2007).
90. Righetti PG, Castagna A, Antonucci F et al. Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin. Chim. Acta 357(2), 123-139 (2005).
91. Luque-Garcia JL, Neubert TA. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J. Chromatogr. A 1153(1-2), 259-276 (2007).
92. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin. Chem. 51(1), 3-5 (2007).
93. Fakhfakh F, Ayadi H, Bahloul Z, Jarraya A, Sioud M, Zouali M. Antibody epitopes probed by immunoselected phage-display library peptides in members of a family with various rheumatic manifestations. Clin. Exp. Rheumatol. 14(6), 607-611 (1996).
94. Saito H, Fukuda Y, Katsuragi K et al. Isolation of peptides useful for differential diagnosis of Crohn's disease and ulcerative colitis. Gut 52(4), 535-540 (2003).
95. Geurts P, Fillet M, de Seny D et al. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics 21(14), 3138-3145 (2005).
96. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 100(16), 9440-9445 (2003).
97. Ivanov YD, Govorun VM, Bykov VA, Archakov AI. Nanotechnologies in proteomics. Proteomics 6(5), 1399-1414 (2006).
98. Archakov AI, Ivanov YD. Analytical nanobiotechnology for medicine diagnostics. Mol. Biosyst. 3(5), 336-342 (2007).
99. Archakov AI, Ivanov YD, Lisitsa AV, Zgoda VG. AFM fishing nanotechnology is the way to reverse the Avogadro number in proteomics. Proteomics 7(1), 4-9 (2007).
100. The first prognostic DNA chip validated by IDIBAPS www.medicalnewstoday. com/articles/58206.php